We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Panel of Long Noncoding RNAs Predicts Prospects for Leukemia Survival

By LabMedica International staff writers
Posted on 21 Dec 2014
Cancer researchers have identified a panel of 48 long noncoding RNAs that is indicative of a favorable outcome in older patients suffering from acute myeloid leukemia (AML) and has the potential to aid clinicians in choosing the least toxic, most effective treatment for this disease, which has a three-year survival rate of only 5% to 15%.

Long non-coding RNAs (long ncRNAs, lncRNA) are non-protein coding transcripts longer than 200 nucleotides. More...
This somewhat arbitrary limit distinguishes long ncRNAs from small regulatory RNAs such as microRNAs (miRNAs, short interfering RNAs (siRNAs), Piwi-interacting RNAs (piRNAs), small nucleolar RNAs (snoRNAs), and other short RNAs. While lncRNAs are known to be involved in numerous biological roles including imprinting, epigenetic gene regulation, cell cycle and apoptosis, and metastasis and prognosis in solid tumors, their role in AML has not been clarified.

To determine whether lncRNAs are associated with clinical features and recurrent mutations in older patients (aged over 60 years) with cytogenetically normal (CN)-AML, investigators at Ohio State University (Columbus, USA) evaluated lncRNA expression in 148 untreated older CN-AML patients using a custom microarray platform. An independent set of 71 untreated older patients with CN-AML was used to validate the outcome scores using RNA sequencing.

The investigators derived an lncRNA score comprising 48 lncRNAs. Patients with an unfavorable compared with favorable lncRNA score had a lower complete response rate and shorter disease-free survival. Three years into the study, only 7% of patients with an unfavorable score were disease free compared with 39% of patients with a favorable score. Overall survival at three years for those with an unfavorable score was 10% versus 43% for patients with a favorable score.

“We have identified a pattern of 48 lncRNAs that predicted both response to standard chemotherapy and overall survival in older CN-AML patients,” said first author Dr. Ramiro Garzon, associate professor of internal medicine at Ohio State University.

“Patients in the favorable group had a high probability of responding to standard chemotherapy, while those in the unfavorable group generally responded poorly to the treatment and had worse overall survival.”

The study was published in the December 15, 2014, online edition of the journal Proceedings of the National Academy of Sciences of the United States of America (PNAS).

Related Links:

Ohio State University



Gold Member
Blood Gas Analyzer
Stat Profile pHOx
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gold Member
Hematology Analyzer
Medonic M32B
New
Gold Member
Ketosis and DKA Test
D-3-Hydroxybutyrate (Ranbut) Assay
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The new analysis of blood samples links specific protein patterns to five- and ten-year mortality risk (Photo courtesy of Adobe Stock)

Blood Protein Profiles Predict Mortality Risk for Earlier Medical Intervention

Elevated levels of specific proteins in the blood can signal increased risk of mortality, according to new evidence showing that five proteins involved in cancer, inflammation, and cell regulation strongly... Read more

Hematology

view channel
Image: Research has linked platelet aggregation in midlife blood samples to early brain markers of Alzheimer’s (Photo courtesy of Shutterstock)

Platelet Activity Blood Test in Middle Age Could Identify Early Alzheimer’s Risk

Early detection of Alzheimer’s disease remains one of the biggest unmet needs in neurology, particularly because the biological changes underlying the disorder begin decades before memory symptoms appear.... Read more

Microbiology

view channel
Image: The SMART-ID Assay delivers broad pathogen detection without the need for culture (Photo courtesy of Scanogen)

Rapid Assay Identifies Bloodstream Infection Pathogens Directly from Patient Samples

Bloodstream infections in sepsis progress quickly and demand rapid, precise diagnosis. Current blood-culture methods often take one to five days to identify the pathogen, leaving clinicians to treat blindly... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.